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sity comparable to Americans for Nonsmokers’ 
Rights.
Lott expresses the libertarian view that physi-
cians and governments should stay out of attempts 
to change individual behavior, even if that behav-
ior is harmful. The same argument could be made 
for mandatory use of seat belts in automobiles 
and helmets for motorcycle riders, drunk-driving 
legislation, and the use of fluoride to combat den-
tal caries.4 In the case of tobacco use and obe-
sity, I would be more sympathetic to Lott’s argu-
ment were it not for the huge marketing efforts 
of the tobacco and food industries, which, if un-
opposed, would be even more influential than they 
already are. Although I agree that clinical efforts 
should avoid coercion and stigmatization, I come 
down on the side of urging clinicians to do all they 
can to improve the health of the public.
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Control of Neglected Tropical Diseases
To the Editor: Hotez et al. (Sept. 6 issue)1 pre-
sent an excellent review of current global ap-
proaches to neglected tropical diseases. However, 
vigilant ongoing (post-intervention) surveillance 
to ensure that these diseases do not rebound 
should not be ignored. The integration of dis-
ease-control programs using a “rapid-impact 
package of drugs” is a feasible and probably cost-
effective way to improve the quality of life for 
billions of people. The authors advocate monitor-
ing and evaluation to judge the success of these 
programs but do not emphasize ongoing surveil-
lance. Although surveillance may present a resource 
challenge in many environments, it also poses a 
statistical challenge as these heterogeneously 
distributed parasitic diseases become less com-
mon. A comprehensive, integrated surveillance 
plan should be incorporated into the cost esti-
mates for the control or elimination of neglected 
tropical diseases. New approaches for determin-
ing the burden of these diseases as they become 
less prevalent should include improved diagnos-
tic tools and novel epidemiologic techniques.
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The authors reply: Huppatz and Durrheim 
comment on the need for surveillance. For the ne-
glected tropical diseases, control and surveillance 
strategies are determined by the epidemiology and 
by the precise objectives of the intervention. For 
example, human African trypanosomiasis was 
controlled yet resurged during the period from the 
1960s to the 1990s in Angola, Democratic Repub-
lic of the Congo, and Sudan, because surveillance 
stopped, health systems collapsed, and the mobile-
team approach was abandoned.1 Today, human 
African trypanosomiasis is again under control, 
and effective surveillance is crucial in order to avoid 
a new resurgence. In contrast, soil-transmitted hel-
minthiasis and schistosomiasis require regular 
preventive mass chemotherapy to reduce severe 
morbidity, and subsequent monitoring of lot qual-
ity assurance sampling is enough.2,3 With lym-
phatic filariasis, onchocerciasis, and trachoma, 
surveillance after control must monitor reduc-
tion of transmission. The critical tools referred 
to by Huppatz and Durrheim are being developed 
or deployed. However, cost and expertise are 
constraints on routine use, because health sys-
tems are overburdened and human resources are 
scarce where neglected tropical diseases are 
prevalent. Sadly, introducing routine surveillance 
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of neglected tropical diseases in health manage-
ment information systems will be challenging, 
given the diversity of epidemiology and health 
systems.
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Myocardial Reperfusion Injury
To the Editor: In the article by Yellon and Haus-
enloy (Sept. 13 issue)1 on myocardial perfusion 
injury, I would like to challenge the statement 
about therapeutic hypothermia, since this method 
is emerging as a novel way to reduce final myo-
cardial infarct size. Therapeutic cooling showed 
a significant ST-segment resolution in the group 
with anterior myocardial infarction in the Cooling 
as an Adjunctive Therapy to Percutaneous Interven-
tion in Patients with Acute Myocardial Infarction 
(COOL-MI) trial.2 Patients with anterior-wall in-
farction and a core body temperature of 35°C or 
less before angioplasty had a reduction in the final 
infarct size, as compared with patients with a tem-
perature of more than 35°C. Observations from 
the COOL-MI trial suggest that the heart needs to 
be cooled optimally before reperfusion in order to 
provide optimal myocyte and microvascular pro-
tection.
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To the Editor: Yellon and Hausenloy discuss 
mechanisms of myocyte death. Readers may un-
derestimate the relationship between the “no re-
flow” phenomenon and myocardial reperfusion 
injury.1 Tissue perfusion is an independent pre-
dictor of death after reperfusion and is associat-
ed with infarct size, ventricular function, and the 
presence or absence of congestive heart failure.2 
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Therefore, the no-reflow phenomenon should be 
considered prominently in discussing mechanisms 
of myocardial reperfusion injury.
The authors refer to adenosine as an antiin-
flammatory agent; however, adenosine has other 
actions (antiplatelet, vasodilatory, angiogenic, vas-
culogenic, and antifibrotic).1 Preclinical studies 
have shown cardioprotective effects of adenosine. 
The Acute Myocardial Infarction Study of Adeno-
sine (AMISTAD) I and II showed reductions in 
infarct size in anterior infarction (67% and 57%, 
respectively).1,3 AMISTAD II showed that adeno-
sine given within 3 hours after the onset of symp-
toms decreased mortality at 6 months (7.3% in the 
adenosine group vs. 11.2% in the placebo group).4
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